Drug Profile
Tanomastat
Alternative Names: BAY 12 9566Latest Information Update: 20 Nov 2000
Price :
$50
*
At a glance
- Originator Bayer
- Developer Bayer; National Cancer Institute (Canada)
- Class Antineoplastics; Butyric acids; Small molecules
- Mechanism of Action Angiogenesis inhibitors; Matrix metalloproteinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Non-small cell lung cancer; Osteoarthritis; Ovarian cancer; Pancreatic cancer; Small cell lung cancer
Most Recent Events
- 20 Nov 2000 Results of a phase III study in patients with ovarian cancer have been added to the adverse events and Cancer therapeutic trials section
- 23 May 2000 BAY 129566 is now called tanomastat (INN)
- 07 Mar 2000 A clinical study has been added to the adverse events, pharmacokinetics and pharmacodynamics sections